Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Carboplatin + Gemcitabine + Trilaciclib||Phase II||Actionable||In a Phase II trial, Trilaciclib (G1T28) in combination with Gemzar (gemcitabine) and Paraplatin (carboplatin) were well tolerated in patients with metastatic triple-negative breast cancer, and resulted in an objective response rate of 43% (26/60, all partial responses), a median overall survival of 20.1 months, and a median progression-free survival of 8.8 months, but did not significantly improve myelosuppression (PMID: 31575503; NCT02978716).||31575503|